ReviewExpert review of vaccines2016
DNA-launched live-attenuated vaccines for biodefense applications.
Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- V4020 Venezuelan Equine Encephalitis Vaccine: Mitigating Neuroinvasion and Reversion Through Rational Design.Viruses · 2025Article
- Article
- Replication of the Venezuelan Equine Encephalitis Vaccine from a Synthetic PCR Fragment.Pharmaceutics · 2024Article
- Live-attenuated CHIKV vaccine with rearranged genome replicates in vitro and induces immune response in mice.PLoS neglected tropical diseases · 2024Article
- Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.Viruses · 2024Review
- Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines.Human vaccines & immunotherapeutics · 2022Review
- Article
- Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits.Frontiers in tropical diseases · 2022Article
- The Present and Future of Yellow Fever Vaccines.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A single-dose live attenuated chimeric vaccine candidate against Zika virus.NPJ vaccines · 2021Article
- Infectious RNA vaccine protects mice against chikungunya virus infection.Scientific reports · 2020Article
- Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine.Human vaccines & immunotherapeutics · 2020Article
- Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses.Vaccines · 2020Review
- Review
- Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family.Vaccines · 2019Review
- Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.Journal of virology · 2018Article
- Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice.Virology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.